Hanna Cho1, Jae Yong Choi2,3, Hye Sun Lee4, Jae Hoon Lee2, Young Hoon Ryu5, Myung Sik Lee1, Clifford R Jack6, Chul Hyoung Lyoo7. 1. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 2. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 3. Division of RI-Convergence Research, Korea Institute Radiological and Medical Sciences, Seoul, South Korea. 4. Biostatistics Collaboration Unit, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea; and. 5. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea lyoochel@yuhs.ac ryuyh@yuhs.ac. 6. Department of Radiology, Mayo Clinic, Rochester, Minnesota. 7. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea lyoochel@yuhs.ac ryuyh@yuhs.ac.
Abstract
Tau PET enables in vivo visualization and quantitation of tau accumulation in Alzheimer disease (AD). In cross-sectional tau PET studies, tau burden reflects disease severity and phenotypic variation. We investigated longitudinal changes in cortical tau accumulation and their association with cognitive decline in patients with AD. Methods: We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (18F-flortaucipir and 18F-florbetaben), MRI, and neuropsychologic tests. All participants underwent the same assessments after 2 y. After correcting for partial-volume effect, we created SUV ratio (SUVR) images. By using a linear mixed-effect model, we investigated the changes in SUVR across time within each group. We also investigated a correlation between the progression of tau accumulation and cognitive decline. Results: In contrast to no change in global cortical SUVR in the CU- and CU+ groups during the 2-y period, global cortical SUVR increased by 0.06 (2.9%) in the MCI+ group and 0.19 (8.0%) in the DEM+ group at follow-up. The MCI+ group was associated with additional tau accumulation predominantly in the medial and inferior temporal cortices, whereas the DEM+ group showed increases in the lateral temporal cortex. Progressive tau accumulation occurred in the diffuse cortical areas in the MCI+ patients who developed dementia and the DEM+ patients who showed deterioration of global cognition, whereas there was only a small increase of additional tau accumulation in the lateral temporal cortex in those who did not show worsening of cognition. Deterioration of global cognition and language functions was associated with progression of diffuse tau accumulation in the association neocortex. Conclusion: Progressive tau accumulation occurs in prodromal AD and DEM patients in the cortical areas at different levels of tau accumulation. Progression of cognitive dysfunction may be related to the additional tau accumulation in regions of higher Braak stage. 18F-flortaucipir PET is an imaging biomarker for monitoring the progression of AD.
Tau PET enables in vivo visualization and quantitation of tau accumulation in Alzheimer disease (AD). In cross-sectional tau PET studies, tau burden reflects disease severity and phenotypic variation. We investigated longitudinal changes in cortical tau accumulation and their association with cognitive decline in patients with AD. Methods: We enrolled 107 participants (45 amyloid-β-negative cognitively unimpaired [CU-], 7 amyloid-β-positive cognitively unimpaired [CU+], 31 with prodromal AD [mild cognitive impairment; MCI+], and 24 with AD dementia [DEM+]) who completed 2 baseline PET scans (18F-flortaucipir and 18F-florbetaben), MRI, and neuropsychologic tests. All participants underwent the same assessments after 2 y. After correcting for partial-volume effect, we created SUV ratio (SUVR) images. By using a linear mixed-effect model, we investigated the changes in SUVR across time within each group. We also investigated a correlation between the progression of tau accumulation and cognitive decline. Results: In contrast to no change in global cortical SUVR in the CU- and CU+ groups during the 2-y period, global cortical SUVR increased by 0.06 (2.9%) in the MCI+ group and 0.19 (8.0%) in the DEM+ group at follow-up. The MCI+ group was associated with additional tau accumulation predominantly in the medial and inferior temporal cortices, whereas the DEM+ group showed increases in the lateral temporal cortex. Progressive tau accumulation occurred in the diffuse cortical areas in the MCI+patients who developed dementia and the DEM+ patients who showed deterioration of global cognition, whereas there was only a small increase of additional tau accumulation in the lateral temporal cortex in those who did not show worsening of cognition. Deterioration of global cognition and language functions was associated with progression of diffuse tau accumulation in the association neocortex. Conclusion: Progressive tau accumulation occurs in prodromal AD and DEM patients in the cortical areas at different levels of tau accumulation. Progression of cognitive dysfunction may be related to the additional tau accumulation in regions of higher Braak stage. 18F-flortaucipir PET is an imaging biomarker for monitoring the progression of AD.
Authors: Marilyn S Albert; Steven T DeKosky; Dennis Dickson; Bruno Dubois; Howard H Feldman; Nick C Fox; Anthony Gamst; David M Holtzman; William J Jagust; Ronald C Petersen; Peter J Snyder; Maria C Carrillo; Bill Thies; Creighton H Phelps Journal: Alzheimers Dement Date: 2011-04-21 Impact factor: 21.566
Authors: Hanna Cho; Jae Yong Choi; Mi Song Hwang; Jae Hoon Lee; You Jin Kim; Hye Mi Lee; Chul Hyoung Lyoo; Young Hoon Ryu; Myung Sik Lee Journal: Neurology Date: 2016-06-29 Impact factor: 9.910
Authors: Osama Sabri; Marwan N Sabbagh; John Seibyl; Henryk Barthel; Hiroyasu Akatsu; Yasuomi Ouchi; Kohei Senda; Shigeo Murayama; Kenji Ishii; Masaki Takao; Thomas G Beach; Christopher C Rowe; James B Leverenz; Bernardino Ghetti; James W Ironside; Ana M Catafau; Andrew W Stephens; Andre Mueller; Norman Koglin; Anja Hoffmann; Katrin Roth; Cornelia Reininger; Walter J Schulz-Schaeffer Journal: Alzheimers Dement Date: 2015-03-28 Impact factor: 21.566
Authors: Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo Journal: Ann Neurol Date: 2016-07-08 Impact factor: 10.422
Authors: Val J Lowe; Heather J Wiste; Matthew L Senjem; Stephen D Weigand; Terry M Therneau; Bradley F Boeve; Keith A Josephs; Ping Fang; Mukesh K Pandey; Melissa E Murray; Kejal Kantarci; David T Jones; Prashanthi Vemuri; Jonathan Graff-Radford; Christopher G Schwarz; Mary M Machulda; Michelle M Mielke; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Clifford R Jack Journal: Brain Date: 2018-01-01 Impact factor: 13.501
Authors: Jeffrey S Phillips; Sandhitsu R Das; Corey T McMillan; David J Irwin; Emily E Roll; Fulvio Da Re; Ilya M Nasrallah; David A Wolk; Murray Grossman Journal: Hum Brain Mapp Date: 2017-11-06 Impact factor: 5.038
Authors: Zeshan Ahmed; Jane Cooper; Tracey K Murray; Katya Garn; Emily McNaughton; Hannah Clarke; Samira Parhizkar; Mark A Ward; Annalisa Cavallini; Samuel Jackson; Suchira Bose; Florence Clavaguera; Markus Tolnay; Isabelle Lavenir; Michel Goedert; Michael L Hutton; Michael J O'Neill Journal: Acta Neuropathol Date: 2014-02-16 Impact factor: 17.088
Authors: Greet Vanderlinden; Jenny Ceccarini; Thomas Vande Casteele; Laura Michiels; Robin Lemmens; Eric Triau; Kim Serdons; Jos Tournoy; Michel Koole; Mathieu Vandenbulcke; Koen Van Laere Journal: Mol Psychiatry Date: 2022-07-06 Impact factor: 15.992
Authors: Tharick A Pascoal; Andrea L Benedet; Dana L Tudorascu; Joseph Therriault; Sulantha Mathotaarachchi; Melissa Savard; Firoza Z Lussier; Cécile Tissot; Mira Chamoun; Min Su Kang; Jenna Stevenson; Gassan Massarweh; Marie-Christine Guiot; Jean-Paul Soucy; Serge Gauthier; Pedro Rosa-Neto Journal: Brain Date: 2021-12-16 Impact factor: 15.255
Authors: Suzanne L Baker; Karine Provost; Wesley Thomas; A J Whitman; Mustafa Janabi; Mark E Schmidt; Maarten Timmers; Hartmuth C Kolb; Gil D Rabinovici; William J Jagust Journal: J Cereb Blood Flow Metab Date: 2021-07-14 Impact factor: 6.960